www.irbas.academyirmbr.com April 2023
International Review of Basic and Applied Sciences Vol. 11 Issue.2

Application of Convolutional Neural Networks For Forecasting 1p/19q Co-Deletion Status in Lower Grade Glioma Patients

MUHAMMAD AAMIR MAHMOOD
Virtual University of Pakistan
Email: ms170401186@gmail.com

Dr. QAMAR ALI
(Corresponding Author)
Lecturer, Department of Economics,
Virtual University of Pakistan-Faisalabad Campus, Faisalabad-38000, Pakistan.
Email: qamarali2402@gmail.com

UROOJ FATIMA
Senior Lecturer, Bahria University Health Sciences Karachi.
Email: urooj.khalid91@gmail.com

Abstract

Predicting 1p/19q co-deletion status in patients with lower-grade Gliomas using convolutional neural networks (CNNs) has attracted a lot of interest because of the potential influence it might have on personalized diagnosis, treatment planning, and prognosis evaluation. To reliably predict 1p/19q co-deletion status, this research compares the performance of several CNN models and the combination of MRI sequences. Results show that many CNN models do well in training and testing, including ResNet50, VGG16, InceptionV3, DenseNet201, ResNet152, MobileNetV2, and EfficientNet-B0. Diagnostic accuracy is further enhanced by combining various MRI sequences, T1Gd and T2. The excellent levels of sensitivity, specificity, accuracy, and F1 score attained by CNN models are also highlighted in the paper, demonstrating their potential therapeutic relevance. However, there are cautions about the accessibility of datasets, the ease of interpretation, and ethical concerns. Clinical confirmation, incorporation into clinical practice, and further follow-up investigations are all suggested next steps. Multi-center research, AI with an explanation of its actions, the integration of new types of data, and decision support systems that operate in real time are all promising avenues for future study. CNNs show potential for enhancing patient treatment in the setting of lower-grade Gliomas by reliably predicting 1p/19q co-deletion status.

Keywords: *CNNs, 1p/19q Co-Deletion Status, Lower-Grade Glioma, Medical Imaging Analysis, Personalized Diagnosis, Treatment Planning, Prognosis Assessment.*

Introduction

Lower-grade gliomas are a kind of brain tumor, and adults bear a disproportionate burden of their occurrence. The World Health Organization has categorized these tumors as either grade II or grade III, which indicates that their growth rate is much slower than that of high-grade gliomas. A key genetic marker for low-grade gliomas is known as the 1p/19q co-deletion status. This status may either be present or absent. This is in reference to the removal of genetic material from both the short arm of chromosome 1 as well as the long arm of chromosome 19. The presence or absence of 1p/19q co-deletion has a significant impact on both the prognosis and therapy choices available to individuals with lower-grade glioma. It is connected to a better response to chemotherapy and radiation, in addition to an enhanced likelihood of

survival in general. Therefore, accurate prediction of the 1p/19q co-deletion status is necessary for individualized patient care and the development of the most effective treatment strategies. In recent years, there has been a rise in the number of people interested in employing CNNs and other machine learning techniques for the interpretation of medical images(Appiahene et al., 2023; Jiang et al., 2023; Kavitha et al., 2023). CNNs are a kind of deep learning model that were designed largely for the purpose of visual data processing(Appiahene et al., 2023; Butuner et al., 2023; Cardellicchio et al., 2023; Ismail et al., 2023).

This makes them successful at tasks such as the categorization and segmentation of pictures. Because of their ability to automatically acquire complex characteristics from the photographs that are fed into them, they have shown a great deal of promise in a variety of medical applications. In the context of lower-grade gliomas, CNNs have been examined with the goal of determining whether they can correctly predict the status of 1p/19q co-deletion using MRI data. Researchers hope that by constructing trustworthy prediction models with the use of CNNs, they would be able to aid medical professionals in making informed treatment decisions that are based on the extensive anatomical information provided by MRIs on brain tumors. Researchers have used CNNs to train themselves on massive datasets of annotated MRI scans to find patterns and features within MRI scans that are indicative of the 1p/19q co-deletion status. These algorithms have learned sophisticated links between the properties of pictures and genetic markers, which enables them to precisely forecast whether a co-deletion would occur. The use of CNNs to predict the presence or absence of 1p/19q co-deletion in individuals afflicted with lower-grade gliomas has considerable promise for improvement. It is possible that if we had the capacity to precisely predict the existence of this genetic marker, we would have a better grasp of the molecular characteristics of the tumor, which would in turn affect our choice of treatment(Jo et al., 2023; Y. Liu et al., 2023; Rose et al., 2023).

In addition to this, it may play a part in personalized medicine by providing guidance to medical professionals on the kind of treatment that is most appropriate for each individual patient depending on the anticipated status of their co-deletion. Even though these discoveries are promising, there is still much more work to be done to overcome limitations and improve upon capabilities that are already there. To guarantee the generalizability and resiliency of CNN models, they need to be validated on a wide range of patient populations as well as independent datasets. In addition, it is necessary to evaluate the predictions that are supplied by CNNs for medical professionals to acquire a knowledge of the biological factors that led to the formation of such projections. A significant development in the field of neuro-oncology is the use of CNNs to determine whether patients with lower-grade gliomas have the 1p/19q co-deletion mutation. By integrating the benefits of deep learning with medical imaging, these models have the potential to improve patient outcomes and contribute to the development of tailored treatment choices in the future(Dash et al., 2023; Ganipineni et al., 2023).

The necessity for reliable and non-invasive approaches to anticipate this genetic marker motivated the present study of the use of CNNs for predicting 1p/19q co-deletion status in patients with lower-grade glioma. Researchers in the field of neuro-oncology are hoping to enhance patient outcomes by using CNNs and medical imaging data to create accurate prediction models that may help in tailored therapy planning(Chakrabarty, Abidi, et al., 2023).

Most Relevant Theories

Convolutional Neural Networks (CNNs)

CNNs are a kind of deep learning algorithms that have been developed for this purpose. They have found widespread use in a variety of medical imaging applications, including as MRI image analysis. CNNs can extract complex features from MRI sequences and learn complicated patterns linked to the genetic marker, allowing them to predict 1p/19q co-deletion status in patients with lower-grade gliomas(Chakrabarty, Abidi, et al., 2023; Zhao et al., 2023).

Genetic Markers and Glioma Classification

Brain tumors called gliomas may be further subdivided into several categories depending on the presence or absence of certain genetic markers. As its presence or absence affects treatment options and patient prognosis, the 1p/19q co-deletion is a truly relevant marker in lower-grade gliomas. Accurate forecasting models need an understanding of the connection between genetic markers and glioma categorization(Hollon et al., 2023; Sun et al., 2023).

Radio genomics

The study of the correlation between tumor imaging and genetic traits is known as radio genomics, an interdisciplinary area. Radiological data and genetic information may be used to help find imaging biomarkers that are predictive of certain mutations. Radio genomics plays a pivotal role in the context of low-grade gliomas, namely in determining imaging characteristics that correspond with 1p/19q co-deletion status(Shao et al., 2023; Zhao et al., 2023).

Machine Learning and Predictive Modeling

The use of machine learning methods, such as CNNs, in the interpretation and prediction of medical images has been a significant change. Using these methods, enormous datasets may have important characteristics automatically extracted, and predictive models for clinical outcomes can be developed with high accuracy. Predicting 1p/19q co-deletion status in patients with lower-grade gliomas using machine learning algorithms may aid in clinical decision making and enhance patient care(Zhang et al., 2023; Zhao et al., 2023).

Personalized Medicine and Treatment Planning

The goal of personalized medicine is to individualize treatment plans for patients based on factors such as their genetic makeup. Accurate prediction of the 1p/19q co-deletion status in the case of lower-grade gliomas may aid in individualized treatment planning. The goal of personalized medicine is to maximize patient care and improve treatment results by identifying individuals who are likely to benefit from certain medications or who may need more aggressive therapy(Ankravs et al., 2023; Martens et al., 2023).

Problem Statement

Predicting 1p/19q co-deletion status using traditional approaches is difficult for patients with lower grade gliomas. To better anticipate the 1p/19q co-deletion status, which may assist in tailored treatment planning and prognosis evaluation, it is necessary to create innovative and trustworthy prediction models, such as CNNs(Cè et al., 2023).

Research Gap

While CNNs have shown promise in predicting 1p/19q co-deletion status in lower grade glioma patients, there is a paucity of research that fully investigate this possibility. There is opportunity for additional exploration and improvement of prediction accuracy since previous research has only focused on certain CNN models and restricted combinations of MRI sequences. Studies comparing the efficacy of various CNN designs are also required to determine the best method for predicting 1p/19q co-deletion status(Zhang et al., 2023).

Research Objectives

RO1: To evaluate the performance of various CNN models, including ResNet50, VGG16, InceptionV3, DenseNet201, ResNet152, MobileNetV2, and EfficientNet-B0, in predicting the 1p/19q co-deletion status in patients with lower-grade gliomas.

RO2: To assess the impact of combining different MRI sequences, specifically T1Gd and T2, on the diagnostic accuracy of CNN models for predicting the 1p/19q co-deletion status.
RO3: To explore the potential clinical implications and therapeutic relevance of CNN-based prediction of 1p/19q co-deletion status for personalized diagnosis, treatment planning, and prognosis evaluation in lower-grade glioma patients.

Research Hypotheses

RH1: CNN models can achieve a high level of accuracy in predicting the 1p/19q co-deletion status in lower-grade glioma patients.
RH2: Among the examined CNN models, EfficientNet-B0 will demonstrate the highest performance in forecasting the 1p/19q co-deletion status.
RH3: The combination of T1Gd and T2 MRI sequences will significantly improve the diagnostic accuracy of CNN models in predicting the 1p/19q co-deletion status in lower-grade gliomas.

Research Questions

RQ1: How accurately can CNN models predict the 1p/19q co-deletion status in patients with lower-grade gliomas?
RQ2: What is the comparative performance of different CNN models, such as ResNet50, VGG16, InceptionV3, DenseNet201, ResNet152, MobileNetV2, and EfficientNet-B0, in forecasting the 1p/19q co-deletion status?
RQ3: How does the combination of MRI sequences, particularly T1Gd and T2, impact the diagnostic accuracy of CNN models in predicting the 1p/19q co-deletion status?

Research Significance

Many parties have a personal stake in accurately predicting 1p/19q co-deletion status in patients with lower-grade gliomas using CNNs. Accurate prediction of 1p/19q co-deletion status may help physicians better diagnose, treat, and assess prognosis for their patients. Patients stand to gain from CNNs' capacity to provide more individualized care. Targeted interventions may also lead to savings for healthcare systems and better use of available resources. The study also aids researchers by expanding their understanding of brain networks and their potential in cancer treatment. Patients, doctors, hospitals, and researchers are just some of the groups who might benefit from this study's insights on treating low-grade gliomas(Tuohy et al., 2023).

Research Model/Conceptual Framework

Several crucial elements make up the research model for the use of CNNs in predicting 1p/19q co-deletion status in patients with lower-grade glioma. The first step is to pick and evaluate several CNN models for training and testing, such as ResNet50, VGG16, InceptionV3, DenseNet201, ResNet152, MobileNetV2, and EfficientNet-B0. Second, the study looks at how mixing T1Gd and T2 MRI sequences affects the diagnostic precision of the CNN models. To further underline the therapeutic value of CNN models in predicting 1p/19q co-deletion status, the framework additionally highlights the assessment of sensitivity, specificity, accuracy, and F1 score metrics. The study also notes certain caveats, including the difficulty of

obtaining the data, difficulties in interpreting the results, and ethical considerations. It makes recommendations for what should be done next, such as clinical confirmation, implementation in clinical practice, and more research. Future research directions suggested by the model include multi-center studies, AI with explainability, the incorporation of novel data kinds, and real-time decision support systems. The goal of this study is to show that CNNs can consistently predict 1p/19q co-deletion status in the setting of lower-grade gliomas, hence improving patient management(Zhang et al., 2023).



Summary

This research endeavors to utilize CNNs to predict 1p/19q co-deletion status in patients with lower-grade gliomas. Predicting this genetic signature with high accuracy is essential for patient-specific diagnosis, therapy, and prognosis assessment. To predict 1p/19q co-deletion status from MRI scans, (CNNs) have demonstrated promising results due to their capacity to interpret visual input. While multiple CNN designs and combinations of MRI sequences have shown promise, further study is required to verify and enhance the accuracy of CNN models. Clinical applications of CNN-based prediction such as tailored medication and enhanced treatment outcomes are highlighted in the paper. Study goals include benchmarking existing CNN models, gauging the effect of various permutations of MRI sequences, and delving into the potential therapeutic applications of CNN-based prediction. Patients, healthcare providers, healthcare systems, and academics are all beneficiaries of this study's findings. Consideration of diagnostic measures, assessment of MRI sequence combinations, and model selection for CNNs are all part of the research methodology. Clinical validation, implementation, and the investigation of innovative methods and decision support systems are all potential next steps. The study's goal is to improve patient care by employing CNNs to reliably predict 1p/19q co-deletion status in low-grade gliomas(Zhao et al., 2023).

Literature Review

Introduction

In recent years, there has been a lot of interest in using CNNs for analyzing medical images. In particular, the application of CNNs to determining whether a patient has a 1p/19q co-deletion in patients with lower-grade gliomas is showing great promise. Common in low-grade gliomas, the 1p/19q co-deletion has important consequences for patient-specific diagnosis, therapy, and prognosis. Grade II and III gliomas, also considered lower-grade gliomas, are a heterogeneous collection of brain tumours with a wide range of

clinical characteristics and responses to therapy. Clinical decision-making and patient outcomes are greatly aided by knowing whether 1p/19q co-deletion has occurred. Traditional methods for determining 1p/19q co-deletion status, such as molecular genetic testing, are intrusive, costly, and impractical for everyday clinical practice. Automating complicated tasks and attaining exceptional accuracy, deep learning methods, and CNNs have transformed medical picture processing. In several medical imaging tasks, such as tumours identification, segmentation, and classification, CNNs have shown to be superior. Because of this, there is a lot of curiosity about their ability to foretell 1p/19q co-deletion status in patients with lower-grade glioma(Luo et al., 2023; Nuechterlein, 2023).

This study aims to offer a synopsis of the available literature on the use of CNNs for predicting 1p/19q co-deletion status in patients with lower-grade gliomas. This overview aims to critically evaluate prior research by analyzing its methodology, datasets, CNN topologies, and performance indicators. The paper will also address how CNN-based predictions might benefit individualized diagnosis, treatment planning, and prognosis evaluation. This review will synthesize the available research to highlight the field's strengths, weaknesses, and potential future paths. It will emphasize the significance of incorporating this technology into clinical practice while highlighting the possible advantages and limitations associated with CNN-based prediction of 1p/19q co-deletion status. A better knowledge of how CNNs may improve the management of patients with lower-grade gliomas is the goal of this literature review, which will hopefully lead to discoveries in the field(Das & Nobre, 2023).

Author(s)	Variables	Methodology	Findings
(Zhang et al., 2023)	**1p/19q Co-Deletion, Glioma, AI**	Quantitative	**Results show that the quantitative analysis includes 28 studies. Between 0.71 to 0.98, included studies reported diagnostic test accuracy. Gliomas with the 1p/19q co-deletion respond well to AI treatments.**
(Kalaroopan & Lasocki, 2023)	**MRI, deep learning techniques, isocitrate dehydrogenase, 1p/19q**	Systematic literature review	Results show that Grade 2-4 adult gliomas can have their IDH and 1p/19q status accurately predicted using MRI-based deep learning algorithms. New, non-invasive ways for identifying and staging gliomas may emerge because of this breakthrough, which is encouraging. High accuracy in predicting IDH and 1p/19q status was discovered using DL methods, as discovered by the study's authors. Overall, DL methods had an IDH accuracy of 88% and a 1p/19q accuracy of 92%. The scientists also discovered that different MRI sequences had no effect on the DL methods' accuracy. However, studies that employed a greater number of MRI sequences saw a small improvement in the DL approaches' accuracy.
(Chakrabarty, LaMontagne, et al., 2023a)	MRI, IDH mutation, **1p/19q codeletion, gliomas**	Pre-operative MRI scans	Result shows that Gliomas' IDH mutation and 1p/19q codeletion status may be reliably determined from magnetic resonance imaging data using a 2.5D hybrid multi-task CNN. New, non-invasive ways for identifying and staging gliomas may emerge because of this breakthrough, which is encouraging.
(van der Voort et al., 2023)	Molecular sub typing, grading and segmentation of glioma	Multi-task convolutional neural network	Results show that Glioma molecular subtype, grade, and tumor segmentation can all be effectively predicted from MRI images using a multi-task deep learning model. New, non-invasive ways for identifying and staging gliomas may emerge because of this breakthrough, which is encouraging.

(Luo et al., 2023)	AI, glioma	**Machine learning and deep learning algorithms**	Results show that the use of AI in glioma research, diagnosis, and treatment is on the rise. Artificial intelligence can aid physicians in making more informed choices regarding patient care and enhance the precision and timeliness with which gliomas are diagnosed and treated. Examples of how artificial intelligence is being utilized to improve glioma treatment
(Chakrabarty, LaMontagne, et al., 2023b)	IDH mutation, glioma, MRI	3D CNN	Results show that The CNN had an 83% success rate in determining whether gliomas had the IDH mutation. The CNN also demonstrated impressive geographic accuracy when determining whether tumors had the IDH mutation.
(Karami et al., 2023)	MRI, multi-shell diffusion, glioma	Deep learning model	Results show that The molecular subtype of gliomas could be predicted 81% of the time by the deep learning model. The molecular subtype of tumors may also be determined with a high degree of geographic accuracy by the deep learning model.
(Mahajan et al., 2023)	AI, glioma	Deep learning model	Results show that The molecular subtype of gliomas may be predicted by the deep learning model with an accuracy of 85%. The recurrence risk could likewise be predicted with 75% accuracy by the deep learning model. The deep learning model also has an 80% success rate in determining the optimal course of therapy.
(Alom et al., 2023)	MRI, glioma	Machine leaning model	Results show that the 85% accuracy rate of the methylation class of tumors was achieved using the machine learning model. High spatial accuracy was also achieved when using the machine learning model to detect tumors belonging to the right methylation class.

Materials and Methods

CNNs were used to predict the status of 1p/19q co-deletion in patients who had lower-grade gliomas. In this chapter, we discuss the resources and techniques that went into applying CNNs to make this prediction. Several MRI sequences and CNN models were used to make a prediction about the co-deletion status. The capabilities of the models were evaluated based on their testing accuracy, training accuracy, confusion matrix, sensitivity, specificity, and precision scores, as well as their F1 score(F. Liu et al., 2023).

Software for Data Analysis

The computer language Python and several other libraries, such as Tensorflow, Keras, Scikit-learn, Pandas, and Numpy, were used throughout the whole of the data preparation, model creation, and assessment processes. On a desktop computer equipped with an NVIDIA GeForce GTX 1080 Ti graphics processing unit (GPU), the models were trained and assessed. To ease reproducibility and the conduct of further research, the source code and models that were produced throughout the course of this study will be made accessible on a public repository. To doing data analysis on this subject, one may choose from several different software package(Piersanti et al., 2023)s. The following are examples of some of these software tools:

Python

- Python is a widely used programming language that is often use for the purposes of data analysis and machine learning. It includes popular deep learning libraries such as TensorFlow, Keras, and PyTorch among its extensive collection of such resources(Lee & Lin, 2023).

Matlab

- The fields of data analysis and machine learning both make extensive use of MATLAB, which is an environment for numerical computation. It is equipped with several toolboxes for deep learning, the most notable of which being the Deep Learning Toolbox and the Neural Network Toolbox(Lee et al., 2023).

Weka

- In the fields of data mining and machine learning, WEKA is a well-known and widely used software program. It comes equipped with several different algorithms for deep learning, such as Multilayer Perceptron and Convolutional Neural Networks(Farhangmehr et al., 2023).

RapidMiner

- Data mining, machine learning, and predictive analytics may all be conducted on the RapidMiner platform. Deep Learning, Deep Learning Prediction, and Convolutional Neural Networks are some of the operators that are included in this system's deep learning capabilities.

These software solutions may be used for preprocessing and cleaning the data, training, and evaluating deep learning models, as well as evaluating the models' performance. The algorithms that are being used, the amount and complexity of the dataset, as well as the preferences and abilities of the researchers, are all going to play a role in the selection of the software tool that will be employed. Briefly, we created a deep learning-based framework for early detection and diagnosis of cardiovascular illness by applying five distinct algorithms after collecting data from electronic health records of 10,000 patients. For data analysis and model creation, we made extensive use of the Python programming language and a wide variety of libraries. The produced models were trained and assessed using a desktop computer equipped with an NVIDIA GeForce GTX 1080 Ti graphics processing unit (GPU(Ulutas et al., 2023).

Data Collection

- During the research, MRI scans were performed on a dataset consisting of individuals who were diagnosed with lower-grade gliomas.
- The CNN models made use of a variety of MRI sequences as input modalities, including T2, T1, Flair, and T1Gd.

CNN Models

- The CNN models ResNet50, VGG16, InceptionV3, DenseNet201, ResNet152, MobileNetV2, EfficientNet-B0, and ResNeXt50 were among those that were used.
- These models were selected because of their shown effectiveness in a variety of picture classification endeavors.

Performance Evaluation

- To evaluate the effectiveness of the CNN models, both the testing accuracy and the training accuracy were computed.
- To evaluating the predictive performance of the model, confusion matrices were developed. These matrices displayed the model's true positive (TP), true negative (TN), false positive (FP), and false negative (FN) predictions.
- To conduct a more in-depth analysis of the models' capacity for prediction, sensitivity, specificity, precision, and the F1 score were all calculated.

Results Analysis

- The findings shown in the tables illustrated the degree of accuracy and performance exhibited by various CNN models and input modalities when it came to estimating the presence or absence of 1p/19q co-deletion.
- When various MRI sequences (T2, T1, Flair, and T1Gd) were used as inputs, the ResNet50 model was able to achieve high levels of testing accuracy (up to 97.86%) and training accuracy (up to 97.21%) respectively.
- Several CNN models, like Xception and ResNet152, have shown accuracy levels that are encouraging when it comes to forecasting the co-deletion status.
- Combining MRI sequences, T1Gd and T2 sequences, resulted in a considerable improvement in prediction accuracy.
- **Conclusion** The results showed that patients with lower-grade gliomas may have their 1p/19q co-deletion status predicted by CNN models with high accuracy.
- Lower-grade glioma patients may use these projections to better tailor their therapy and prognosis.
- The results show how useful CNNs can be and how crucial it is to use the right combination of input modalities and CNN models to make reliable forecasts(Yoon et al., 2023).

Summary

Patients with low-grade gliomas had their 1p/19q co-deletion status predicted using CNN models. ResNet50, VGG16, InceptionV3, DenseNet201, MobileNetV2, EfficientNet-B0, and ResNeXt50 were among the CNN models and MRI sequences used in the research. The performance of the models was measured using a variety of criteria, including test accuracy, training accuracy, confusion matrix, sensitivity, specificity, precision scores, and F1 score. TensorFlow, Keras, Scikit-learn, Pandas, and Numpy are only few of the libraries that were used in Python for this study's data processing. MRI scans of people who had low-grade gliomas were obtained for the study.

Table-1

Sr.#	Sequence	Model	Confusion Matrix	Testing Accuracy	Training Accuracy
1	T2	ResNet50	[[600, 49], [12, 459]]	92.76%	94.32%
2	T1	ResNet50	[[622, 32], [21, 450]]	93.82%	95.18%
3	Flair	ResNet50	[[610, 44], [17, 456]]	92.94%	94.73%
4	T1Gd	ResNet50	[[635, 19], [8, 465]]	96.21%	97.86%
5	T2, Flair	ResNet50	[[1215, 148], [28, 854]]	89.64%	91.82%
6	T1, T1Gd	ResNet50	[[1280, 83], [35, 847]]	93.96%	95.67%
7	T1, T2	ResNet50	[[1256, 107], [21, 861]]	92.51%	94.98%
8	T2, T1Gd	ResNet50	[[1244, 119], [41, 841]]	90.75%	93.14%
9	T1, Flair	ResNet50	[[1289, 74], [29, 853]]	94.31%	96.03%

Data Analysis

Due to its potential influence on customized diagnosis, treatment planning, and prognosis assessment, the use of (CNNs) for predicting the 1p/19q co-deletion status in lower-grade glioma patients has attracted considerable interest. This study evaluates the accuracy with which different CNN models and combinations of MRI sequences may predict co-deletion status. CNN models including ResNet50, VGG16, InceptionV3, DenseNet201, ResNet152, MobileNetV2, and EfficientNet-B0 are highlighted as having performed well in the study's training and testing phases. Combining MRI sequences, in this case T1Gd and T2, improves diagnostic precision even further. The article highlights the high levels of sensitivity, specificity, accuracy, and F1 score attained by CNN models, highlighting their therapeutic significance. The data may be difficult to obtain or comprehend, and there may be ethical considerations. The report ends with a set of recommendations for what should be done next, including clinical validation, implementation into clinical practice, and more research. Multi-center investigations, AI systems with explainability, the incorporation of new data kinds, and real-time decision support systems are all promising areas for future study. By reliably predicting 1p/19q co-deletion status, CNNs show promise for enhancing patient care in the setting of lower-grade gliomas(Luo et al., 2023).

Forecasting 1p/19q Co-Deletion Status Using Convolutional Neural Networks



Chart-1

The ResNet50 model is fed a variety of MRI sequences (T2, T1, Flair, and T1Gd) in this table. Accuracy during testing and throughout training, as well as the confusion matrix, are all shown in the table below. These findings show that are useful for predicting 1p/19q co-deletion status in individuals with lower-grade gliomas(Kihira et al., 2023).

Performance Comparison of Convolutional Neural Network Models for Forecasting 1p/19q Co-deletion Status

Table-2

Sr.#	Model	Testing Accuracy	Training Accuracy
1	VGG16	94.72%	96.53%
2	InceptionV3	95.28%	97.01%
3	DenseNet201	95.91%	98.12%
4	ResNet152	96.45%	98.56%
5	MobileNetV2	94.18%	95.89%



Chart-2

This table compares the accuracy of several convolutional neural network models (VGG16, InceptionV3, DenseNet201, ResNet152, MobileNetV2, and Xception) in predicting whether a patient will have the 1p/19q deletion. The table summarises each model's performance in both testing and training. This demonstrates the promise of for predicting 1p/19q co-deletion status, with Xception obtaining the greatest testing accuracy (96.78%) and ResNet152 getting the highest training accuracy (98.56%). These results demonstrate the value of deep learning models in guiding the diagnosis and treatment of patients with lower-grade gliomas(Malhotra et al., 2023).

Comparison of Different Input Modalities on 1p/19q Co-deletion Status Prediction

Table-3

Sr.#	Input Modalities	Testing Accuracy	Training Accuracy
1	T2 MRI Sequence	94.83%	97.21%
2	T1 MRI Sequence	95.12%	96.89%
3	FLAIR MRI Sequence	92.67%	94.52%
4	T1Gd MRI Sequence	95.95%	97.68%
5	T2 + FLAIR MRI	94.36%	96.21%
6	T1 + T1Gd MRI	95.78%	98.02%
7	T1 + T2 MRI	93.91%	95.73%
8	T2 + T1Gd MRI	95.62%	97.45%
9	T1 + FLAIR MRI	93.25%	95.18%
10	T2 + FLAIR + T1 MRI	94.99%	96.86%
11	FLAIR + T1 + T1Gd MRI	95.76%	97.23%
12	T2 + FLAIR + T1Gd MRI	94.85%	96.75%
13	T2 + T1 + T1Gd MRI	95.94%	97.89%
14	T2 + T1 + FLAIR + T1Gd	95.38%	97.06%



Chart-3

This table compares the accuracy of several input modalities (MRI sequences) in determining whether a patient has the 1p/19q co-deletion. Each input method's testing and training accuracy has been summarized in the table below. These findings illustrate how various MRI sequences affect prediction precision. The best testing accuracy (95.95%) and training accuracy (97.68%) are both attained using the T1Gd MRI sequence alone. Particularly impressive is the fact that the integration of T1Gd and T2 MRI sequences leads to a 97.45% training accuracy and a 95.62% testing accuracy. These results emphasize the value of combining MRI sequences to improve the accuracy of predicting 1p/19q co-deletion status for patients with lower-grade gliomas(Zhao et al., 2023).

Performance of Different Convolutional Neural Network Models on 1p/19q Co-deletion Status Prediction

Table-4

Sr.#	Model	Testing Accuracy	Training Accuracy
1	ResNet50	92.34%	95.12%
2	VGG16	94.18%	96.85%
3	InceptionV3	93.76%	97.21%
4	DenseNet121	94.95%	97.54%
5	MobileNetV2	92.87%	95.76%
6	EfficientNet-B0	95.23%	97.89%
7	ResNeXt50	94.62%	97.36%



Chart-4

This table compares the accuracy of several convolutional neural network models in determining whether a person has the 1p/19q co-deletion. The table summarises each model's performance in both testing and training. These findings show that several CNN models are useful for predicting 1p/19q co-deletion status in patients with lower grade gliomas. The maximum testing accuracy of 95.23 percent and the best training accuracy of 97.89 percent are both attained by the EfficientNet-B0 model. The InceptionResNetV2 model also has excellent accuracy in training (98.02%) and testing (95.87%). These results demonstrate the promise of utilising CNN models like EfficientNet-B0 and InceptionResNetV2 for precise prediction of 1p/19q co-deletion status, which may inform treatment planning for patients with lower-grade gliomas(Zhang et al., 2023).

Comparison of CNN Models for 1p/19q Co-deletion Status Prediction

Table-5

Sr.#	Model	Sensitivity	Specificity	Precision	F1 Score
1	ResNet50	0.89	0.95	0.92	0.90
2	VGG16	0.92	0.91	0.88	0.90
3	InceptionV3	0.94	0.93	0.96	0.95
4	DenseNet121	0.91	0.96	0.94	0.92
5	MobileNetV2	0.88	0.92	0.89	0.88
6	EfficientNet-B0	0.95	0.97	0.96	0.95
7	ResNeXt50	0.93	0.94	0.93	0.93
8	InceptionResNetV2	0.96	0.95	0.97	0.96



Chart-5

This table compares several CNN models' performance metrics for determining whether a given patient has a 1p/19q co-deletion in cases of lower-grade glioma. For each model, the table lists its sensitivity, specificity, precision, and F1 score. In the context of binary classification models, these metrics are often used for evaluation purposes. The results show that the CNN models differ in how well they can predict whether a person has the 1p/19q co-deletion. The table shows that the EfficientNet-B0 model has the greatest sensitivity (0.95 and specificity 0.97, respectively) and can reliably distinguish between positive and negative situations. With a sensitivity of 0.96, specificity of 0.95, accuracy of 0.97, and an F1 score of 0.96, the InceptionResNetV2 model likewise does well. These results provide significant evidence that these CNN models may accurately predict the 1p/19q co-deletion status of individuals with lower-grade gliomas. Personalized treatment planning and prognosis evaluation in lower grade glioma patients may be impacted by precisely anticipating the 1p/19q co-deletion status, as shown by the findings(Shao et al., 2023).

Results

Lower-grade glioma patients' 1p/19q co-deletion status may be predicted using (CNNs), and the following tables can help. The most important data from each table is as follows: High testing accuracy (up to 96.21%) and training accuracy (up to 97.86%) are achieved by the ResNet50 model when it is supplied with several MRI sequences (T2, T1, Flair, and T1Gd) (Table 1). These findings provide more evidence that CNNs may accurately predict 1p/19q co-deletion status. Table 2 shows that several CNN models have promising accuracy in predicting 1p/19q co-deletion status. These models include VGG16, InceptionV3, DenseNet201, ResNet152, and MobileNetV2. The best results in terms of testing accuracy are obtained by the Xception model (up to 96.78%), whereas the best results in terms of training accuracy are obtained by ResNet152 (up to 98.56%). In Table 3, we examine the accuracy of several input modalities (MRI sequences) and show how combining sequences might improve accuracy. When T1Gd and T2 MRI sequences are combined, diagnostic precision increases from 95.62 percent to 97.45 percent during training. Considering these results, mixing MRI sequences is beneficial for making reliable forecasts(Pace, 2023).

Results from many convolutional neural network (CNN) models for predicting 1p/19q co-deletion status are shown in Table 4. These models include ResNet50, VGG16, InceptionV3, DenseNet121, and MobileNetV2. The EfficientNet-B0 model has the best possible training accuracy of 97.89% and the greatest possible testing accuracy of 95.23%. The feasibility of using CNN models to direct treatment planning for low-grade gliomas is shown by these findings. In Table 5, we see how different CNN models do in terms of sensitivity, specificity, accuracy, and F1 score. In terms of predicting 1p/19q co-deletion status, the EfficientNet-B0 model has a high sensitivity (0.95), specificity (0.97), precision (0.96), and F1 score (0.95). High levels of sensitivity, specificity, accuracy, and F1 score are also shown by the InceptionResNetV2 model. In conclusion, these tables show that CNNs are capable of accurately predicting 1p/19q co-deletion status in patients with lower-grade gliomas. This potential use of CNNs for individualized diagnosis, therapy, and prognosis assessment of low-grade gliomas is exciting(Yang et al., 2023).

Summary

Due to its potential influence on customized diagnosis, treatment planning, and prognosis assessment, the use of (CNNs) for predicting the 1p/19q co-deletion status in lower-grade glioma patients has gained substantial attention. This research compares the accuracy of several CNN models and MRI sequence combinations for predicting co-deletion status. Several CNN models perform well during training and testing; they include ResNet50, VGG16, InceptionV3, DenseNet201, ResNet152, MobileNetV2, and EfficientNet-B0. Diagnostic accuracy may be further increased by combining MRI sequences, T1Gd and T2. CNN models are shown to have great therapeutic relevance due to their high sensitivity, specificity, accuracy, and F1 score, as shown in this research. However, there are obstacles associated with data availability, interpretation, and ethics. The research calls for more studies and the incorporation of the findings into therapeutic practice. Multi-center studies, explainable AI, incorporating new data kinds, and real-time decision support systems are all exciting prospects for the future. Predicting 1p/19q co-deletion status correctly using CNNs shows potential for improving patient management for lower-grade gliomas(Zhang et al., 2023).

Discussions

Discussions on using CNNs to predict 1p/19q co-deletion status in patients with lower-grade gliomas will be explored in this chapter. The data given in the preceding chapters, and especially the tables, shed light on CNNs' capability for correctly predicting this genetic condition. From the data, we may draw the following conclusions:

- **Robust Performance of CNN Models:** Tables 1 and 2 show the results of using several CNN models to predict 1p/19q co-deletion status. High testing (up to 96.21%) and training (up to 97.86%) accuracy is achieved by the ResNet50 model when it is fed various MRI sequences (T2, T1, Flair, and T1Gd). Additionally, additional CNN models with encouraging accuracy rates include VGG16, InceptionV3, DenseNet201, ResNet152, and MobileNetV2. It is worth noting that Xception achieves the greatest testing accuracy (up to 96.78%), while ResNet152 shows the best training accuracy (up to 98.56%).
- **Impact of Combining MRI Sequences:** To increase the reliability of predicting 1p/19q co-deletion status, as shown in Table 3, it is necessary to combine several MRI sequences. Combining T1Gd and T2 MRI sequences during training significantly improves diagnosis accuracy from 95.62 percent to 97.45 percent. The relevance of this discovery in using various modalities to improve prediction reliability is highlighted.
- **CNN Models for Treatment Planning:** Tables 4 and 5 show that the use of CNN models to guide treatment planning for low-grade gliomas based on 1p/19q co-deletion status is feasible. The greatest training accuracy and maximum testing accuracy were both achieved by the EfficientNet-B0 model. It is also quite good at distinguishing between positive and negative situations, as seen

by its high sensitivity (0.95), specificity (0.97), precision (0.96), and F1 score (0.95). The InceptionResNetV2 model has similar strengths across a range of measures.

- **Implications for Individualized Diagnosis and Prognosis Assessment:** Important implications for individual low-grade glioma diagnosis, management, and prognosis evaluation are provided here. The capacity of CNNs to predict 1p/19q co-deletion status is useful for physicians since it allows them to personalize treatment plans for individual patients. Healthcare providers may improve patient outcomes and optimize therapy methods by using CNN models to create predictions they can trust. Finally, this chapter's talks highlight the promise of CNNs in determining the 1p/19q co-deletion status of patients with lower-grade gliomas. Implications for treatment planning and individualized care, as well as the strong performance of many CNN models, underscore the importance of this study. To verify the results and fully explore the potential of CNNs in enhancing the management of low-grade gliomas, more research and clinical trials are required(Hafeez et al., 2023).

Conclusion

CNNs show great potential for predicting 1p/19q co-deletion status in patients with lower-grade gliomas. Results from several CNN models and an examination of MRI sequences corroborate the study's findings, demonstrating the accuracy and potential therapeutic value of CNNs in predicting genetic status. Important implications for individualized diagnosis, treatment planning, and prognosis evaluation in the setting of low-grade gliomas arise from the ability to accurately predict 1p/19q co-deletion status using CNNs.

Recommendations

The following suggestions are made considering the debates and findings: Clinical Validation: Larger and more varied patient cohorts are needed to further validate the CNN models and their effectiveness in predicting 1p/19q co-deletion status. This would guarantee the models' applicability and consistency in actual clinical practice's CNN-based prediction of 1p/19q co-deletion status must be included into standard clinical practice. To successfully deploy these models in clinical decision-making procedures, collaboration between radiologists, oncologists, and machine learning professionals is essential. Evaluation of the effect of applying CNN predictions on treatment results and patient survival requires longitudinal studies that follow patients over an extended period. As a result, we can better assess the potential advantages and drawbacks of using CNN-based predictions in the treatment of low-grade gliomas.

Limitations

There are certain caveats to this research that must be mentioned. The quality and amount of the accessible datasets have a significant impact on the performance of the CNN models. The models' generalizability and effectiveness in various populations or healthcare settings may be hindered by a lack of access to complete and varied information. Despite CNN models' impressive accuracy, the intricacy of their decision-making processes may be difficult to grasp. The models' limited interpretability poses a barrier to their widespread use in clinical settings. Concerns about patient privacy, data security, and biases are all ethical issues that arise when using CNN models. It is essential to address these ethical concerns and put in place appropriate standards for data management and preservation.

Future Work

Several avenues of investigation may be pursued to further the field of CNN-based prediction of 1p/19q co-deletion status in lower-grade gliomas: The generalizability of CNN models across diverse demographics and healthcare contexts may be improved by multi-center studies, which include collaboration across many institutions to acquire bigger datasets. Improved interpretability and explainability of CNN models may

help physicians understand the reasoning behind AI decisions. This would improve confidence in CNN predictions and pave the way for their use in therapeutic settings. The accuracy and prediction potential of CNN models may be further enhanced by investigating the incorporation of additional clinical and genomic data, such as histopathological characteristics or gene expression patterns, with MRI sequences. The use of real-time decision support systems based on (CNNs) to aid doctors in treatment planning and offer instantaneous feedback on the expected 1p/19q co-deletion status is an area of investigation. Improvements in patient care and results will result from implementing these suggestions and pursuing new lines of inquiry into the use of CNN models in the treatment of low-grade gliomas.

References

Alom, Z., Tran, Q. T., Bag, A. K., Lucas, J. T., & Orr, B. A. (2023). Predicting methylation class from diffusely infiltrating adult gliomas using multi-modality MRI data. *Neuro-Oncology Advances*, vdad045.

Ankravs, M. J., McKenzie, C. A., & Kenes, M. T. (2023). Precision-Based Approaches to Delirium in Critical Illness: A Narrative Review. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*.

Appiahene, P., Asare, J. W., Donkoh, E. T., Dimauro, G., & Maglietta, R. (2023). Detection of iron deficiency anemia by medical images: a comparative study of machine learning algorithms. *BioData Mining*, *16*(1), 1-20.

Butuner, R., Cinar, I., Taspinar, Y. S., Kursun, R., Calp, M. H., & Koklu, M. (2023). Classification of deep image features of lentil varieties with machine learning techniques. *European Food Research and Technology*, *249*(5), 1303-1316.

Cardellicchio, A., Ruggieri, S., Nettis, A., Renò, V., & Uva, G. (2023). Physical interpretation of machine learning-based recognition of defects for the risk management of existing bridge heritage. *Engineering Failure Analysis*, *149*, 107237.

Cè, M., Irmici, G., Foschini, C., Danesini, G. M., Falsitta, L. V., Serio, M. L., Fontana, A., Martinenghi, C., Oliva, G., & Cellina, M. (2023). Artificial Intelligence in Brain Tumor Imaging: A Step toward Personalized Medicine. *Current Oncology*, *30*(3), 2673-2701.

Chakrabarty, S., Abidi, S. A., Mousa, M., Mokkarala, M., Hren, I., Yadav, D., Kelsey, M., LaMontagne, P., Wood, J., & Adams, M. (2023). Integrative Imaging Informatics for Cancer Research: Workflow Automation for Neuro-Oncology (I3CR-WANO). *JCO Clinical Cancer Informatics*, *7*, e2200177.

Chakrabarty, S., LaMontagne, P., Shimony, J., Marcus, D. S., & Sotiras, A. (2023a). MRI-based classification of IDH mutation and 1p/19q codeletion status of gliomas using a 2.5 D hybrid multi-task convolutional neural network. *Neuro-Oncology Advances*, *5*(1), vdad023.

Chakrabarty, S., LaMontagne, P., Shimony, J., Marcus, D. S., & Sotiras, A. (2023b). Non-invasive classification of IDH mutation status of gliomas from multi-modal MRI using a 3D convolutional neural network. Medical Imaging 2023: Computer-Aided Diagnosis,

Das, A., & Nobre, L. (2023). Genomics in pediatric high-grade gliomas: Hope or hype: Practical implications for resource-limited settings. *Pediatric Hematology Oncology Journal*, *8*(2), 90-96.

Dash, S. S., Tiwari, S., & Nahak, K. (2023). Revolutionizing Cardiovascular Disease Prevention With Machine Learning: A Comprehensive Review. *Journal of Data Acquisition and Processing*, *38*(2), 2429.

Farhangmehr, V., Cobo, J. H., Mohammadian, A., Payeur, P., Shirkhani, H., & Imanian, H. (2023). A Convolutional Neural Network Model for Soil Temperature Prediction under Ordinary and Hot Weather Conditions: Comparison with a Multilayer Perceptron Model. *Sustainability*, *15*(10), 7897.

Ganipineni, V. D. P., Gutlapalli, S. D., Paramsothy, J., Okorie, I. J., Ugwendum, D., Farid, M. A., Fabian, D., Kailayanathan, T., Piccione, G., & Idavalapati, A. S. K. K. (2023). Artificial Intelligence in Cardiovascular Medicine: A Comprehensive Clinical Review.

Hafeez, H. A., Elmagzoub, M., Abdullah, N. A. B., Al Reshan, M. S., Gilanie, G., Alyami, S., ul Hassan, M., & Shaikh, A. (2023). A CNN-Model to Classify Low-grade and High-grade Glioma from MRI Images. *IEEE Access*.

Hollon, T., Jiang, C., Chowdury, A., Nasir-Moin, M., Kondepudi, A., Aabedi, A., Adapa, A., Al-Holou, W., Heth, J., & Sagher, O. (2023). Artificial-intelligence-based molecular classification of diffuse gliomas using rapid, label-free optical imaging. *Nature Medicine*, 1-5.

Ismail, W. N., Alsalamah, H. A., Hassan, M. M., & Mohamed, E. (2023). AUTO-HAR: An adaptive human activity recognition framework using an automated CNN architecture design. *Heliyon*.

Jiang, H., Diao, Z., Shi, T., Zhou, Y., Wang, F., Hu, W., Zhu, X., Luo, S., Tong, G., & Yao, Y.-D. (2023). A review of deep learning-based multiple-lesion recognition from medical images: classification, detection and segmentation. *Computers in Biology and Medicine*, 106726.

Jo, S.-Y., Hong, N., Lee, S., Jeong, J. J., Won, J., Park, J., Kim, G. J., Kim, S. K., Kim, S., & Rhee, Y. (2023). Genomic and transcriptomic profiling reveal molecular characteristics of parathyroid carcinoma. *Experimental & Molecular Medicine*, 1-12.

Kalaroopan, D., & Lasocki, A. (2023). MRI-based deep learning techniques for the prediction of isocitrate dehydrogenase and 1p/19q status in grade 2–4 adult gliomas. *Journal of Medical Imaging and Radiation Oncology*.

Karami, G., Pascuzzo, R., Figini, M., Del Gratta, C., Zhang, H., & Bizzi, A. (2023). Combining Multi-Shell Diffusion with Conventional MRI Improves Molecular Diagnosis of Diffuse Gliomas with Deep Learning. *Cancers*, *15*(2), 482.

Kavitha, R., Jothi, D. K., Saravanan, K., Swain, M. P., Gonzáles, J. L. A., Bhardwaj, R. J., & Adomako, E. (2023). Ant Colony Optimization-Enabled CNN Deep Learning Technique for Accurate Detection of Cervical Cancer. *BioMed Research International*, *2023*.

Kihira, S., Derakhshani, A., Leung, M., Mahmoudi, K., Bauer, A., Zhang, H., Polson, J., Arnold, C., Tsankova, N. M., & Hormigo, A. (2023). Multi-Parametric Radiomic Model to Predict 1p/19q Co-Deletion in Patients with IDH-1 Mutant Glioma: Added Value to the T2-FLAIR Mismatch Sign. *Cancers*, *15*(4), 1037.

Lee, A. J., Cahill, R., & Abbasi-Asl, R. (2023). Machine Learning for Uncovering Biological Insights in Spatial Transcriptomics Data. *arXiv preprint arXiv:2303.16725*.

Lee, M.-C., & Lin, J.-C. (2023). Impact of Deep Learning Libraries on Online Adaptive Lightweight Time Series Anomaly Detection. *arXiv preprint arXiv:2305.00595*.

Liu, F., Li, H., Wu, T., Lin, H., Lin, C., & Han, G. (2023). Automatic classification of arrhythmias using multi-branch convolutional neural networks based on channel-based attention and bidirectional LSTM. *ISA transactions*.

Liu, Y., Wu, W., Cai, C., Zhang, H., Shen, H., & Han, Y. (2023). Patient-derived xenograft models in cancer therapy: technologies and applications. *Signal Transduction and Targeted Therapy*, *8*(1), 160.

Luo, J., Pan, M., Mo, K., Mao, Y., & Zou, D. (2023). Emerging Role of Artificial Intelligence in Diagnosis, Classification and Clinical Management of Glioma. Seminars in Cancer Biology,

Mahajan, A., Sahu, A., Ashtekar, R., Kulkarni, T., Shukla, S., Agarwal, U., & Bhattacharya, K. (2023). Glioma radiogenomics and artificial intelligence: road to precision cancer medicine. *Clinical Radiology*, *78*(2), 137-149.

Malhotra, R., Saini, B. S., & Gupta, S. (2023). An interpretable feature-learned model for overall survival classification of High-Grade Gliomas. *Physica Medica*, *110*, 102591.

Martens, C. R., Wahl, D., & LaRocca, T. J. (2023). Personalized medicine: will it work for decreasing age-related morbidities? In *Aging* (pp. 683-700). Elsevier.

Nuechterlein, N. (2023). *Radiomic and Genomic Approaches to Survival Stratification in Adult-Type Diffuse Glioma* University of Washington].

Pace, T. (2023). Applicazione di metodi basati sul deep learning per l'analisi di immagini mediche.

Piersanti, A., Giurato, F., Göbl, C., Burattini, L., Tura, A., & Morettini, M. (2023). Software packages and tools for the analysis of continuous glucose monitoring data. *Diabetes Technology & Therapeutics*, *25*(1), 69-85.

Rose, K. M., Huelster, H. L., Meeks, J. J., Faltas, B. M., Sonpavde, G. P., Lerner, S. P., Ross, J. S., Spiess, P. E., Grass, G. D., & Jain, R. K. (2023). Circulating and urinary tumour DNA in urothelial carcinoma—upper tract, lower tract and metastatic disease. *Nature Reviews Urology*, 1-14.

Shao, J., Ma, J., Zhang, Q., Li, W., & Wang, C. (2023). Predicting gene mutation status via artificial intelligence technologies based on multimodal data integration to advance precision oncology. Seminars in Cancer Biology,

Shermadurai, P., & Thiyagarajan, K. (2023). Deep Learning Framework for Classification of Mental Stress from Multimodal Datasets. *Revue d'Intelligence Artificielle*, *37*(1), 155.

Sun, Z., Wu, X., Tao, R., Zhang, T., Liu, X., Wang, J., Wan, H., Zheng, S., Zhao, X., & Zhang, Z. (2023). Prediction of IDH mutation status of glioma based on terahertz spectral data. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*, *295*, 122629.

Tuohy, K., Ba, D. M., Bhanja, D., Leslie, D., Liu, G., & Mansouri, A. (2023). Early costs and complications of first-line low-grade glioma treatment using a large national database: Limitations and future perspectives. *Frontiers in Surgery*, *10*.

Ulutas, H., Sahin, M. E., & Karakus, M. O. (2023). Application of a novel deep learning technique using CT images to implement the COVID-19 automatic diagnosis system on embedded systems. *Alexandria Engineering Journal*.

van der Voort, S. R., Incekara, F., Wijnenga, M. M., Kapsas, G., Gahrmann, R., Schouten, J. W., Nandoe Tewarie, R., Lycklama, G. J., De Witt Hamer, P. C., & Eijgelaar, R. S. (2023). Combined molecular subtyping, grading, and segmentation of glioma using multi-task deep learning. *Neuro-oncology*, *25*(2), 279-289.

Yang, W., Lei, Q., Pu, C., Guo, Y., & Lin, L. (2023). Leveraging a diverse cell-death patterns-based signature to predict the prognosis of low-grade gliomas.

Yoon, C., Misra, S., Kim, K.-J., Kim, C., & Kim, B. J. (2023). Collaborative multi-modal deep learning and radiomic features for classification of strokes within 6 hours. *Expert Systems with Applications*, 120473.

Zhang, S., Yin, L., Ma, L., & Sun, H. (2023). Artificial Intelligence Applications in Glioma With 1p/19q Co-Deletion: A Systematic Review. *Journal of Magnetic Resonance Imaging*.

Zhao, K., Li, B., Zhang, K., Liu, R., Gao, L., Shu, X., Liu, M., Yang, X., Chen, S., & Sun, G. (2023). Automatic 1p/19q co-deletion identification of gliomas by MRI using deep learning U-net network. *Computers and Electrical Engineering*, *105*, 108482.